Supernus Pharmaceuticals Inc
LSE:0LB2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Supernus Pharmaceuticals Inc
LSE:0LB2
|
US |
|
Foghorn Therapeutics Inc.
NASDAQ:FHTX
|
US |
|
Prosegur Compania de Seguridad SA
OTC:PGCSF
|
ES |
|
C
|
Comfort Systems USA Inc
F:9CF
|
US |
|
Lineage Inc
NASDAQ:LINE
|
US |
|
A
|
Avantor Inc
SWB:AVG
|
US |
|
Swisscom AG
F:SWJ
|
CH |
|
Aya Gold & Silver Inc
TSX:AYA
|
CA |
|
M
|
MGIC Investment Corp
SWB:MGC
|
US |
|
EMCOR Group Inc
NYSE:EME
|
US |
|
I
|
Intesa Sanpaolo SpA
LSE:0HBC
|
IT |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
US |
|
BKW AG
F:B9W
|
CH |
|
F
|
First Majestic Silver Corp
F:FMV
|
CA |
|
C
|
Cross Country Healthcare Inc
F:XXY
|
US |
|
Manhattan Associates Inc
NASDAQ:MANH
|
US |
|
V
|
Vale SA
XBER:CVLC
|
BR |
|
Coveo Solutions Inc
OTC:CVOSF
|
CA |
|
O
|
Omnicell Inc
F:OC9
|
US |
|
M
|
MS&AD Insurance Group Holdings Inc
XBER:59M
|
JP |
|
G
|
Galapagos NV
F:GXEA
|
BE |
Wall St Price Targets
0LB2 Price Targets Summary
Supernus Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for 0LB2 is 63.74 USD with a low forecast of 55.25 USD and a high forecast of 68.92 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 0LB2's stock price target?
Price Target
63.74
USD
According to Wall Street analysts, the average 1-year price target for 0LB2 is 63.74 USD with a low forecast of 55.25 USD and a high forecast of 68.92 USD.
What is the Revenue forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 61%. The projected CAGR for the next 8 years is 8%.
What is the Operating Income forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
62%
The compound annual growth rate for Operating Income over the next 8 years is 62%.
